Nature research paper: NSD2 inhibitors rewire chromatin to treat lung and pancreatic cancers
go.nature.com/458lmmL
go.nature.com/458lmmL
NSD2 inhibitors rewire chromatin to treat lung and pancreatic cancers - Nature
A highly potent and selective small-molecule catalytic inhibitor of the protein lysine methyltransferase NSD2 shows therapeutic efficacy in preclinical models of KRAS-driven pancreatic cancer and lung cancer.
go.nature.com
August 12, 2025 at 8:03 AM
Nature research paper: NSD2 inhibitors rewire chromatin to treat lung and pancreatic cancers
go.nature.com/458lmmL
go.nature.com/458lmmL
Nature research paper: NSD2 targeting reverses plasticity and drug resistance in prostate cancer
go.nature.com/3XmxA6v
go.nature.com/3XmxA6v
NSD2 targeting reverses plasticity and drug resistance in prostate cancer - Nature
Inhibition of the histone methyltransferase NSD2 and the androgen receptor in preclinical models can reverse lineage plasticity to suppress tumour growth and promote cell death in multiple subtypes of castration-resistant prostate cancer.
go.nature.com
November 26, 2025 at 7:23 PM
Nature research paper: NSD2 targeting reverses plasticity and drug resistance in prostate cancer
go.nature.com/3XmxA6v
go.nature.com/3XmxA6v
Spatial partitioning of NSD2 defines H3K36me2 as an active mark for repetitive sequence activation www.nature.com/articles/s4...
September 20, 2026 at 2:15 PM
Spatial partitioning of NSD2 defines H3K36me2 as an active mark for repetitive sequence activation www.nature.com/articles/s4...
Ectopic H3K36me2 can be targeted in cancer with potent small molecules that inhibit NSD2. Work from Or Gozani and collaborators.
new out in Nature www.nature.com/articles/s41...
NSD2 inhibitors rewire chromatin to treat lung and pancreatic cancers - Nature
A highly potent and selective small-molecule catalytic inhibitor of the protein lysine methyltransferase NSD2 shows therapeutic efficacy in preclinical models of KRAS-driven pancreatic cancer and...
www.nature.com
August 8, 2025 at 10:55 AM
Ectopic H3K36me2 can be targeted in cancer with potent small molecules that inhibit NSD2. Work from Or Gozani and collaborators.
Anna Baj, PhD student, shared data showing that NSD2, overexpressed in t(4;14) myeloma, mediates DNA methylation. Higher DNA methylation in NDS2-high, t(4;14) myeloma may also signal vulnerability to epigenetic modulatory agents. #IMS26
September 26, 2026 at 8:25 AM
Anna Baj, PhD student, shared data showing that NSD2, overexpressed in t(4;14) myeloma, mediates DNA methylation. Higher DNA methylation in NDS2-high, t(4;14) myeloma may also signal vulnerability to epigenetic modulatory agents. #IMS26
new out in Nature www.nature.com/articles/s41...
NSD2 inhibitors rewire chromatin to treat lung and pancreatic cancers - Nature
A highly potent and selective small-molecule catalytic inhibitor of the protein lysine methyltransferase NSD2 shows therapeutic efficacy in preclinical models of KRAS-driven pancreatic cancer and...
www.nature.com
August 8, 2025 at 10:24 AM
new out in Nature www.nature.com/articles/s41...
Epigenetics Update - NSD2 targeting reverses plasticity and drug resistance in prostate cancer go.nature.com/4imgShn
Chao Lu and Michael M. Shen (Columbia University) in Nature
#Epigenetics #ProstateCancer #NSD2 #H3K36me2
---
Empower your research with: epigenometech.com
Chao Lu and Michael M. Shen (Columbia University) in Nature
#Epigenetics #ProstateCancer #NSD2 #H3K36me2
---
Empower your research with: epigenometech.com
November 28, 2025 at 11:32 AM
Epigenetics Update - NSD2 targeting reverses plasticity and drug resistance in prostate cancer go.nature.com/4imgShn
Chao Lu and Michael M. Shen (Columbia University) in Nature
#Epigenetics #ProstateCancer #NSD2 #H3K36me2
---
Empower your research with: epigenometech.com
Chao Lu and Michael M. Shen (Columbia University) in Nature
#Epigenetics #ProstateCancer #NSD2 #H3K36me2
---
Empower your research with: epigenometech.com
A new paper in which we could contribute structural insights to the great biochemical work from our collaborators from UNC Chapel Hill. Sascha Amann from our lab was yet again able to solve several very challenging structures. This time of a SCF with Protac and target www.nature.com/articles/s41...
April 23, 2026 at 2:46 PM
A new paper in which we could contribute structural insights to the great biochemical work from our collaborators from UNC Chapel Hill. Sascha Amann from our lab was yet again able to solve several very challenging structures. This time of a SCF with Protac and target www.nature.com/articles/s41...
New Epigenome Technologies Blog post! bit.ly/4ashyOo
"NSD2 and H3K36me2: Revealing the Basis for Prostate Cancer Cell Lineage Plasticity and Uncovering Therapeutic Strategies"
Based on a Nature article by Chao Lu and Michael M. Shen
#EpigenomeTech #Blog #ProstateCancer #Cancer #NSD2 #H3K36me2
"NSD2 and H3K36me2: Revealing the Basis for Prostate Cancer Cell Lineage Plasticity and Uncovering Therapeutic Strategies"
Based on a Nature article by Chao Lu and Michael M. Shen
#EpigenomeTech #Blog #ProstateCancer #Cancer #NSD2 #H3K36me2
February 18, 2026 at 4:56 PM
New Epigenome Technologies Blog post! bit.ly/4ashyOo
"NSD2 and H3K36me2: Revealing the Basis for Prostate Cancer Cell Lineage Plasticity and Uncovering Therapeutic Strategies"
Based on a Nature article by Chao Lu and Michael M. Shen
#EpigenomeTech #Blog #ProstateCancer #Cancer #NSD2 #H3K36me2
"NSD2 and H3K36me2: Revealing the Basis for Prostate Cancer Cell Lineage Plasticity and Uncovering Therapeutic Strategies"
Based on a Nature article by Chao Lu and Michael M. Shen
#EpigenomeTech #Blog #ProstateCancer #Cancer #NSD2 #H3K36me2
WATCH: Amin Sobh, PhD, discusses findings from a study investigating the immune surveillance–modulating capabilities of NSD2 overexpression in multiple myeloma. @theaacr.bsky.social #AACR25 #mmsm #hematology
www.onclive.com/view/dr-sobh...
www.onclive.com/view/dr-sobh...
Dr Sobh on the Effects of NSD2 Overexpression in Multiple Myeloma
Amin Sobh, PhD, discusses findings from a study investigating the immune surveillance–modulating capabilities of NSD2 overexpression in multiple myeloma.
www.onclive.com
April 29, 2025 at 10:42 PM
WATCH: Amin Sobh, PhD, discusses findings from a study investigating the immune surveillance–modulating capabilities of NSD2 overexpression in multiple myeloma. @theaacr.bsky.social #AACR25 #mmsm #hematology
www.onclive.com/view/dr-sobh...
www.onclive.com/view/dr-sobh...
Epigenetics Update - NSD2 inhibitors rewire chromatin to treat lung and pancreatic cancers go.nature.com/4mtd2Uj
#Epigenetics #Chromatin #NSD2 #Cancer #H3K36me2
---
Empower your research with high-res epigenetic insights at epigenometech.com
#Epigenetics #Chromatin #NSD2 #Cancer #H3K36me2
---
Empower your research with high-res epigenetic insights at epigenometech.com
August 7, 2025 at 1:06 PM
Epigenetics Update - NSD2 inhibitors rewire chromatin to treat lung and pancreatic cancers go.nature.com/4mtd2Uj
#Epigenetics #Chromatin #NSD2 #Cancer #H3K36me2
---
Empower your research with high-res epigenetic insights at epigenometech.com
#Epigenetics #Chromatin #NSD2 #Cancer #H3K36me2
---
Empower your research with high-res epigenetic insights at epigenometech.com
NSD2 deficiency disrupts the epigenetic landscape of cochlear hair cells to enhance ECM expression and to perturb cochlear hair cell function https://www.biorxiv.org/content/10.64898/2026.09.21.753379v1
September 23, 2026 at 8:30 AM
NSD2 deficiency disrupts the epigenetic landscape of cochlear hair cells to enhance ECM expression and to perturb cochlear hair cell function https://www.biorxiv.org/content/10.64898/2026.09.21.753379v1
NSD2 deficiency disrupts the epigenetic landscape of cochlear hair cells to enhance ECM expression and to perturb cochlear hair cell function https://www.biorxiv.org/content/10.64898/2026.09.21.753379v1
September 23, 2026 at 8:30 AM
NSD2 deficiency disrupts the epigenetic landscape of cochlear hair cells to enhance ECM expression and to perturb cochlear hair cell function https://www.biorxiv.org/content/10.64898/2026.09.21.753379v1
NSD2 inhibitors rewire chromatin to treat lung and pancreatic cancers | Nature www.nature.com/articles/s41...
NSD2 inhibitors rewire chromatin to treat lung and pancreatic cancers - Nature
A highly potent and selective small-molecule catalytic inhibitor of the protein lysine methyltransferase NSD2 shows therapeutic efficacy in preclinical models of KRAS-driven pancreatic cancer and...
www.nature.com
August 7, 2025 at 12:38 AM
NSD2 inhibitors rewire chromatin to treat lung and pancreatic cancers | Nature www.nature.com/articles/s41...
new out in Nature www.nature.com/articles/s41...
NSD2 targeting reverses plasticity and drug resistance in prostate cancer - Nature
Inhibition of the histone methyltransferase NSD2 and the androgen receptor in preclinical models can reverse lineage plasticity to suppress tumour growth and promote cell death in multiple subtypes of...
www.nature.com
November 26, 2025 at 5:25 PM
new out in Nature www.nature.com/articles/s41...
February 16, 2026 at 11:43 AM
NSD2 inhibitors rewire chromatin to reverse drug resistance for lung, prostate, & pancreatic cancers @nature.com @columbiauniversity.bsky.social @stanforduniversity.bsky.social @mdanderson.bsky.social @mcgilluniversity.bsky.social
www.nature.com/articles/s41...
www.nature.com/articles/s41...
www.nature.com/articles/s41...
www.nature.com/articles/s41...
November 26, 2025 at 5:27 PM
NSD2 inhibitors rewire chromatin to reverse drug resistance for lung, prostate, & pancreatic cancers @nature.com @columbiauniversity.bsky.social @stanforduniversity.bsky.social @mdanderson.bsky.social @mcgilluniversity.bsky.social
www.nature.com/articles/s41...
www.nature.com/articles/s41...
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Amin Sobh, Ph.D., a research assistant professor who works in the lab of our director, @jdlicht.bsky.social, was interviewed by OncLive about his research on the role of NSD2 in multiple myeloma. ⬇️
#AACR25
@theaacr.bsky.social
#AACR25
@theaacr.bsky.social
WATCH: Amin Sobh, PhD, discusses findings from a study investigating the immune surveillance–modulating capabilities of NSD2 overexpression in multiple myeloma. @theaacr.bsky.social #AACR25 #mmsm #hematology
www.onclive.com/view/dr-sobh...
www.onclive.com/view/dr-sobh...
Dr Sobh on the Effects of NSD2 Overexpression in Multiple Myeloma
Amin Sobh, PhD, discusses findings from a study investigating the immune surveillance–modulating capabilities of NSD2 overexpression in multiple myeloma.
www.onclive.com
April 30, 2025 at 12:32 PM
Amin Sobh, Ph.D., a research assistant professor who works in the lab of our director, @jdlicht.bsky.social, was interviewed by OncLive about his research on the role of NSD2 in multiple myeloma. ⬇️
#AACR25
@theaacr.bsky.social
#AACR25
@theaacr.bsky.social
New H3K36me2 CUTANA™ antibody for CUT&RUN and CUT&Tag 🧬
Validated with SNAP-CUTANA controls and NSD2 knockout cells, plus strong performance in translational research.
Explore here: https://www.epicypher.com/product/h3k36me2-cutana-cutrun-and-cuttag-antibody/
Validated with SNAP-CUTANA controls and NSD2 knockout cells, plus strong performance in translational research.
Explore here: https://www.epicypher.com/product/h3k36me2-cutana-cutrun-and-cuttag-antibody/
March 31, 2026 at 5:01 PM
New H3K36me2 CUTANA™ antibody for CUT&RUN and CUT&Tag 🧬
Validated with SNAP-CUTANA controls and NSD2 knockout cells, plus strong performance in translational research.
Explore here: https://www.epicypher.com/product/h3k36me2-cutana-cutrun-and-cuttag-antibody/
Validated with SNAP-CUTANA controls and NSD2 knockout cells, plus strong performance in translational research.
Explore here: https://www.epicypher.com/product/h3k36me2-cutana-cutrun-and-cuttag-antibody/
Structural basis of NSD2 degradation via targeted recruitment of SCF-FBXO22 pubmed.ncbi.nlm.nih.gov/40909644/ #cryoem
September 6, 2025 at 9:14 PM
Structural basis of NSD2 degradation via targeted recruitment of SCF-FBXO22 pubmed.ncbi.nlm.nih.gov/40909644/ #cryoem
RRID:SCR_019152 was used by the authors of the Blood Journal paper "NSD2 drives t(4;14) myeloma cell dependence on adenylate kinase 2 by diverting one-carbon metabolism to the epigenome". RRIDs like this improve reproducibility in scientific research. #accelerateopenscience #reproducibility
doi.org
March 12, 2025 at 7:01 AM
RRID:SCR_019152 was used by the authors of the Blood Journal paper "NSD2 drives t(4;14) myeloma cell dependence on adenylate kinase 2 by diverting one-carbon metabolism to the epigenome". RRIDs like this improve reproducibility in scientific research. #accelerateopenscience #reproducibility
Studies have shown that the NSD2 protein fuels cancer growth, particularly in difficult-to-treat cancers with KRAS mutations.
A new multi-institutional study confirmed that NSD2 can be targeted with a new drug. Learn more: spr.ly/6015fcGXS #OncSky #EndCancer
A new multi-institutional study confirmed that NSD2 can be targeted with a new drug. Learn more: spr.ly/6015fcGXS #OncSky #EndCancer
Novel drug confirms NSD2 protein as therapeutic target in lung and pancreatic cancers
Novel drug confirms NSD2 protein as therapeutic target in lung and pancreatic cancers
spr.ly
August 7, 2025 at 9:00 PM
Studies have shown that the NSD2 protein fuels cancer growth, particularly in difficult-to-treat cancers with KRAS mutations.
A new multi-institutional study confirmed that NSD2 can be targeted with a new drug. Learn more: spr.ly/6015fcGXS #OncSky #EndCancer
A new multi-institutional study confirmed that NSD2 can be targeted with a new drug. Learn more: spr.ly/6015fcGXS #OncSky #EndCancer
Structural basis of NSD2 degradation via targeted recruitment of SCF-FBXO22 pubmed.ncbi.nlm.nih.gov/42026065/ #cryoem
April 24, 2026 at 2:50 PM
Structural basis of NSD2 degradation via targeted recruitment of SCF-FBXO22 pubmed.ncbi.nlm.nih.gov/42026065/ #cryoem